Highlight
- Mortality from cardiogenic shock decreases with increasing hospital cardiac capability tiers.
- Advanced centers offering cardiac surgery and heart transplant/LVAD support exhibit the lowest in-hospital mortality rates.
- Transfer-in status generally increases mortality risk, but this transfer penalty is mitigated at higher-tier centers equipped for complex cardiac care.
- Regionalized hub-and-spoke systems promoting timely referral to high-capability centers improve outcomes for cardiogenic shock patients.
Study Background
Cardiogenic shock is a critical condition characterized by inadequate tissue perfusion due to severe cardiac dysfunction, often complicating acute myocardial infarction or advanced heart failure. Despite advances in mechanical circulatory support and revascularization techniques, short-term mortality remains alarmingly high, underscoring the need to optimize care delivery models. Prior investigations have suggested that hospital expertise and resources might influence outcomes, but the independent impact of institutional cardiac capability tiers—especially factoring in patient instability and interhospital transfer—remains incompletely understood. Understanding these relationships is essential for structuring networks of care to improve patient survival.
Study Design
This retrospective cohort study utilized the National Inpatient Sample database spanning 2016 to 2022, encompassing over 1.17 million hospitalizations for cardiogenic shock across the United States. Hospitals were stratified into five hierarchical tiers reflecting cardiac procedural capability: from tier 1 (non-percutaneous coronary intervention [PCI]-capable hospitals) to tier 5 centers offering heart transplant and durable left ventricular assist device (LVAD) implantation. A latent construct termed Acute Severity was developed incorporating indicators of clinical instability, including cardiac arrest, acute kidney and liver injury, and mechanical ventilation.
The primary endpoint was in-hospital mortality. Generalized structural equation modeling was employed to assess the association between hospital tier and mortality while adjusting for baseline patient characteristics, acute severity, and transfer-in status.
Key Findings
Of the estimated 1,177,180 cardiogenic shock hospitalizations, the greatest proportion occurred at tier 4 (cardiac surgical) and tier 5 (heart transplant/LVAD) centers. Crude mortality showed a graded decline across tiers, from 64.4% in tier 1 hospitals to 36.5% in tier 5 centers.
After multivariable adjustment, hospital tier remained independently associated with mortality reduction. Compared with tier 1 hospitals, odds ratios (ORs) for death progressively decreased in higher tiers: tier 2 (OR 0.43, 95% CI 0.38-0.48), tier 3 (OR 0.37, 95% CI 0.32-0.43), tier 4 (OR 0.34, 95% CI 0.30-0.38), and tier 5 (OR 0.36, 95% CI 0.31-0.41). This demonstrates robust mortality benefit associated with higher institutional cardiac capabilities.
Transfer-in status independently correlated with increased mortality (OR 1.36, 95% CI 1.30-1.43), reflecting the clinical instability and potential treatment delays in transferred patients. Notably, the increased risk associated with transfer was attenuated at tiers 4 and 5 centers, indicating that advanced, resource-rich institutions can mitigate the “transfer penalty.”
Expert Commentary
The study provides powerful evidence supporting the centralization of cardiogenic shock care within regionalized networks, highlighting that advanced cardiac capabilities are crucial in reducing mortality. The creation and validation of a latent acute severity marker strengthens adjustment for illness severity beyond administrative coding alone.
However, residual confounding is possible, as administrative databases may lack granular clinical detail regarding timing, hemodynamics, and specifics of pre-transfer management. The observational design limits causal inference, though the large sample size and consistent tier-associated gradients enhance confidence.
These findings align with evolving guideline recommendations that advocate early identification and prompt transfer of cardiogenic shock patients to high-volume, advanced cardiac centers capable of timely mechanical circulatory support, complex revascularization, and advanced therapies such as transplantation or durable LVAD implantation.
Conclusion
Higher hospital cardiac capability is independently associated with significantly reduced mortality in cardiogenic shock patients. The transfer penalty commonly observed is diminished at specialized cardiac surgical and transplant centers, underscoring the benefit of regionalized, tiered care systems. Implementing early referral pathways and robust hub-and-spoke models may improve survival by ensuring prompt access to advanced therapies. Future studies should prospectively validate these models and investigate strategies to optimize transfer logistics and resource allocation.
Funding and ClinicalTrials.gov
No specific funding source was disclosed. This was an observational analysis of a national administrative dataset, and no clinical trial registration applies.
References
- Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update. Eur Heart J. 2017;38(32):2402–2411. doi:10.1093/eurheartj/ehx278
- McCarthy FH, Murphy ET, Kiernan MS, et al. Changes in the hospital mortality rate in patients with acute myocardial infarction–related cardiogenic shock: clinical experience from the SHOCK trial and registry. JAMA Cardiol. 2018;3(5):413-420. doi:10.1001/jamacardio.2018.0184
- O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742c84
- Khera R, Kolte D, Khera S, et al. Temporal trends and outcomes of patients with cardiogenic shock complicating STEMI. Am J Med. 2020;133(10):1215-1223. doi:10.1016/j.amjmed.2020.04.027
- Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in the time of coronavirus disease 2019. JAMA Cardiol. 2020;5(7):739–740. doi:10.1001/jamacardio.2020.1326
